Secondary Immunodeficiencies and Infections in patients with hematologic malignancies treated with anti-CD20-antibodies

Secondary Immunodeficiencies and Infections in patients with hematologic malignancies treated with anti-CD20-antibodies - SIDI-20

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023404

Enrollment

200

Registered

2021-02-16

Start date

2021-04-08

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell lymphomas C82 C83.0 C83.1 C83.3 C83.5 C83.7 C85.1 C91.1 C91.4

Interventions

Group 1: Adult patients from hematology / oncology group practices who suffer from B-cell lymphomas and are in need of therapy. Patients are to receive 1st line therapy with an anti-CD20 antibody (rit

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of a B-cell lymphoma in need of therapy. Planned 1st line therapy with an anti-CD20 antibody (rituximab, obinutuzumab, ofatumumab). Age = 18 years, signed informed consent, sufficient knowledge of German language

Exclusion criteria

Exclusion criteria: Antibody therapy started before inclusion

Design outcomes

Primary

Measure	Time frame
Frequency and severity of infections. This parameter is measured with the help of a patient diary. After the start of therapy, a monthly status of infections is captured over a period of 12 months.	—

Secondary

Measure	Time frame
Frequency of IgG deficiencies? Therapy of infections? Frequency of immunoglobulin substitutions? IgG substitution corresponding to guidelines?	—

Countries

Germany

Contacts

Public ContactStefan Feiten

Institut für Versorgungsforschung in der Onkologie

s.feiten@invo-koblenz.de0261 / 921 5693-23

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026